New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 26, 2012
06:11 EDTUBS, FLO, GSK, NOK, SIOn the Fly: Periodicals Wrap-Up
WALL STREET JOURNAL: Switzerland and the U.K. announced punitive measures against UBS (UBS) following the unauthorized trading scandal that led to losses of $2.3B at the bank. Swiss financial market regulator Finma said it will watch UBS's investment bank for the foreseeable future and may ask it to raise fresh capital, while the U.K. Financial Services Authority fined UBS $47.6M, the Wall Street Journal reports...Flowers Foods (FLO) could be interested in Twinkies and other products owned by Hostess Brands, and is considered a likely bidder for some of the assets owned by Hostess, the Wall Street Journal reports...REUTERS: The euro zone finance ministers and the IMF will seek to unfreeze the second bailout package for Greece today, but first need to agree if some of the official loans might eventually be forgiven to cut Greek debt, Reuters reports...GlaxoSmithKline (GSK) has no plans to delist its Indian consumer products arm GlaxoSmithKline Consumer Healthcare, said David Redfern, chief strategy officer, Reuters reports...BLOOMBERG: Home equity lines of credit that fueled a spending spree during the U.S.property boom are back. Following six years of declines, lending for so-called Helocs will increase 30% to $79.6B this year, the highest level since the start of the 2008 financial crisis, according to the economics research unit of Moody’s Corp. It projects a 31% jump to $104B next year, Bloomberg reports...Nokia Siemens Networks (NOK, SI) is targeting the U.S. market where Chinese rivals face political hurdles and rising data use entices carriers to spend. The venture is forgoing less lucrative deals in Africa and the Middle East, said CEO Rajeev Suri, Bloomberg reports.
News For UBS;FLO;GSK;NOK;SI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 22, 2014
07:49 EDTGSKGlaxoSmithKline sees FY14 dividend to rise 3% to 80p, 2015 dividend flat
Subscribe for More Information
07:48 EDTGSKGlaxoSmithKline announces restructuring program for pharmaceuticals business
Subscribe for More Information
07:46 EDTGSKGlaxoSmithKline to explore IPO of minority shareholding in ViiV Healthcare
Glaxo announced "further significant steps" within its Pharmaceuticals business to realize value for shareholders and deliver improved operational performance. Glaxo stated: "Five years ago, we created ViiV Healthcare, a new standalone global business focused on development of treatments for HIV. This has been a highly innovative and successful venture with our equity partners Pfizer and Shionogi. The business has made very significant progress in both R&D and commercial execution, culminating in the recent successful launches of Tivicay and Triumeq. We believe now is the right time to explore the potential for an IPO of a minority shareholding in this business. This will provide greater visibility of the intrinsic value we see in its currently marketed assets and future pipeline and also enhance potential future strategic flexibility."
07:44 EDTGSKGlaxoSmithKline backs FY14 view for core EPS 'broadly similar' to FY13
GlaxoSmithKline (GSK) continues to expect full year 2014 core EPS to be broadly similar to 2013 at CER and on ex-divestment basis. Glaxo says its proposed 3-part transaction with Novartis (NVS) is on track for completion in 1H15.
07:42 EDTGSKGlaxoSmithKline reports Q3 core EPS 27.9p, up 5% CER ex-divestments
Subscribe for More Information
06:41 EDTGSKWHO fast-tracking testing of two Ebola vaccines, Guardian reports
Subscribe for More Information
06:39 EDTNOKMicrosoft Lumia to replace Nokia brand, The Verge reports
Microsoft plans to make Microsoft Lumia the new brand name that takes the place of Nokia for the software maker, reports The Verge. Nokia still exists as a separate company without its phones business, focusing on mapping and network infrastructure. Reference Link
October 21, 2014
11:04 EDTGSKGlaxoSmithKline receives orphan status for dabrafenib
The FDA granted GlaxoSmithKline orphan status for dabrafenib, its possible treatment of patients with BRAF mutation positive non-small cell lung cancer.
08:31 EDTUBSEU fines JPMorgan, UBS, Credit Suisse for cartel on derivatives
The European Commission has found that four international banks, RBS (RBS), UBS (UBS), JP Morgan (JPM) and Credit Suisse (CS), operated a cartel on bid-ask spreads of Swiss franc interest rate derivatives in the European Economic Area. The Commission imposed fines worth a total of EUR 32.36M. RBS received immunity from fines for revealing the existence of the cartel to the Commission. UBS and JPMorgan received reductions of their respective fines for cooperating with the investigation under the Commission's 2006 Leniency Notice. UBS was fined EUR 12.65M, JP Morgan fined EUR 10.53M and Credit Suisse was fined EUR 9.17M.
08:18 EDTUBSBasel Committee accelerating work on leverage ratio, FT says
The Basel Committee on Banking Supervision will begin work on the calibration of the leverage ratio, a measure of bank capital seen as less vulnerable to manipulation, sooner than previously planned, which suggests the finished rule could be released as soon as 2015 or 2016, which is ahead of the previous target date of 2017, reported Financial Times, citing comments from the secretary-general of the committee, William Coen. Publicly traded large U.S. banks include Bank of America (BAC), Citigroup (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC). Publicly traded large EU banks include Banco Santander (SAN), Barclays (BCS), Credit Suisse (CS), Deutsche Bank (DB), HSBC (HSBC), ING Groep (ING), Lloyds Banking (LYG), Royal Bank of Scotland (RBS) and UBS (UBS). Reference Link
08:12 EDTUBSJPMorgan, UBS, Credit Suisse to be fined by EU over Libor rigging, Reuters says
JPMorgan (JPM), UBS (UBS) and Credit Suisse (CS) will be fined $115M collectively for their roles in rigging Swiss franc Libor rates, with JPMorgan's fine of $89M making up the lion's share of the penalty, said Reuters, citing a person familiar, who added that Royal Bank of Scotland (RBS) would not be penalized for its own role since it alerted the European Commission to the issue. Reference Link
07:06 EDTGSKFierce Biotech to hold a breakfast meeting
Subscribe for More Information
October 20, 2014
09:09 EDTGSKEMA encourages applications for orphan designation for Ebola treatments
The European Medicines Agency encourages developers of treatments or vaccines against Ebola to apply for orphan designation. Applications for orphan designation of Ebola medicines will be treated as a priority and EMA has committed to fast-tracking their evaluation, the regulator announced. Drug companies that are working on experimental Ebola vaccines and treatments include Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX), NewLink Genetics (NLNK) and GlaxoSmithKline (GSK).
07:21 EDTUBSFederal Reserve Bank of New York and Boston to hold a workshop
Subscribe for More Information
07:19 EDTGSKIBC Life Sciences to hold a conference
Subscribe for More Information
07:12 EDTSICongress of Neurological Surgeons to hold annual meeting
Subscribe for More Information
07:11 EDTSIAmerican Society for Reproductive Medicine to hold annual meeting
2014 Annual Meeting of ASRM is being held in Honolulu on October 18-22.
October 19, 2014
14:03 EDTUBSUBS stays with risky Puerto Rico bond fund recommendations, Reuters says
Despite numerous arbitration claims by investors who cite Puerto Rico closed-end bond funds for losses, UBS has told brokers that they may continue to recommend the funds, says Reuters. Reference Link
October 17, 2014
14:50 EDTGSKBARDA asks labs to ramp up Zmapp production, Reuters says
Subscribe for More Information
11:17 EDTGSKGSK says Ebola vaccine too late for current epidemic, BBC reports
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use